English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The arteriovenous oxygen difference (a-vO2 difference), a measure of peripheral muscle oxygen extraction-utilization during exercise, is reduced in antiretroviral-treated patients with human immunodeficiency virus (HIV), thus causing a shift in the cardiac output-oxygen consumption (Q-VO2) relationship. We investigated the impact of recombinant human GH (rhGH) treatment on a-vO2 difference and the Q-VO2 relationship during submaximal exercise by randomizing 12 HIV-infected patients (mean ± sem: age, 43.3 ± 1.5 yr; body mass, 69.5 ± 2.9 kg; body mass index, 22.4 ± 0.9 kg/m2; maximum oxygen consumption, 33.6 ± 1.5 ml/kg·min), with documented unintentional weight loss (≥10% within the preceding 12 months) despite antiretroviral therapy, to receive 3 months of rhGH (6 mg/d) in a double-blind, placebo-controlled, cross-over trial. We assessed Q (determined noninvasively using CO2 rebreathing), and subsequently a-vO2 difference, from Q-VO2 relationships. At study entry, the mean slope (8.1 ± 1.0 liters/min·1-liter increase in VO2) and intercept (3.1 ± 1.3 liters/min), generated from each patient’s Q-VO2 relationship, were greater and lower, respectively, than those reported for healthy individuals (6.0 and 4.0, respectively), thereby indicating a deficit in the a-vO2 difference. After 3 months of rhGH treatment, the slope decreased to 7.0, and the intercept increased to 3.5. After 1 month of rhGH treatment, the a-vO2 difference (at a VO2 of 1250 ml/min) significantly (P &amp;lt; 0.05) increased (17.1 ± 8.9%) from baseline (9.92 ± 0.51 ml/dl) and remained elevated (10.39 ± 0.48 ml/dl) after 3 months of treatment. No significant changes were seen with placebo. Therefore, treatment with rhGH leads to an improvement in peripheral muscle oxygen extraction-utilization and the Q-VO2 relationship during exercise in patients with HIV-associated wasting despite antiretroviral therapy.

the journal of clinical endocrinology and metabolism/journal of clinical endocrinology and metabolism

Growth Hormone Treatment Improves Peripheral Muscle Oxygen Extraction-Utilization during Exercise in Patients with Human Immunodeficiency Virus-Associated Wasting: A Randomized Controlled Trial